Boehringer to pay $650m to settle Pradaxa litigation
This article was originally published in Scrip
Executive Summary
German drug maker Boehringer Ingelheim said it will pay $650m to settle about 4,000 lawsuits against the company in the US involving its oral blood-thinning agent Pradaxa (dabigatran etexilate mesylate).